GlassScriptPhysician profile
Anna M Antonowich
NPI 1215063268
$4,196.26
in general payments reported to CMS, 2019-2025
42 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $73.50 · 2023: $1,209 · 2024: $967 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451 · Education: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,451.21 |
| Education | $459.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $483.51 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $351.60 | 2023-2025 | Tagrisso, Imfinzi, Enhertu |
| Astellas Pharma US INC | $345.88 | 2025 | Xtandi |
| Glaxosmithkline, LLC. | $314.84 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $307.61 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.58 | 2023-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $202.89 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $168.34 | 2021-2025 | Ultomiris |
| Genentech USA, INC. | $164.72 | 2023-2025 | Tecentriq, Venclexta, Itovebi |
| Rigel Pharmaceuticals, INC. | $162.78 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Lilly USA, LLC | $126.54 | 2023-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $99.90 | 2023-2025 | Darzalex, Carvykti, Tecvayli |
| Eisai INC. | $91.44 | 2023-2025 | |
| Celgene Corporation | $82.53 | 2023-2025 | Opdualag, Reblozyl, Opdivo |
| Abbvie INC. | $81.66 | 2023-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Antonowich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.